Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors

References

• TacarOSriamornsakPDassCRDoxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systemsJ Pharm Pharmacol201365215717023278683
   PubMed Web of Science ®Google Scholar
• PeerDKarpJMHongSFarokhzadOCMargalitRLangerRNano-carriers as an emerging platform for cancer therapyNat Nanotechnol200721275176018654426
   PubMed Web of Science ®Google Scholar
• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyCancer Res20137382412241723423979
   PubMed Web of Science ®Google Scholar
• NobleCOKirpotinDBHayesMEDevelopment of ligand-targeted liposomes for cancer therapyExpert Opin Ther Targets20048433535315268628
   PubMed Web of Science ®Google Scholar
• TaHTDassCRDunstanDEInjectable chitosan hydrogels for localised cancer therapyJ Control Release2008126320521618258328
   PubMed Web of Science ®Google Scholar
• KhemtongCKessingerCWGaoJPolymeric nanomedicine for cancer MR imaging and drug deliveryChem Commun (Camb)2009243497351019521593
   PubMed Web of Science ®Google Scholar
• HuangXEl-SayedIHQianWEl-SayedMACancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorodsJ Am Chem Soc200612862115212016464114
   PubMed Web of Science ®Google Scholar
• LiuKKZhengWWWangCCCovalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapyNanotechnology2010213131510620634575
   PubMed Web of Science ®Google Scholar
• DavisMEThe first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinicMol Pharm20096365966819267452
   PubMed Web of Science ®Google Scholar
• HerbertsonRATebbuttNCLeeFTPhase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersClin Cancer Res200915216709671519825951
   PubMedGoogle Scholar
• O’NealDPHirschLRHalasNJPayneJDWestJLPhoto-thermal tumor ablation in mice using near infrared-absorbing nanoparticlesCancer Lett2004209217117615159019
   PubMed Web of Science ®Google Scholar
• DabbaghAMahmoodianRAbdullahBJAbdullahHHamdiMAbu KasimNHLow-melting-point polymeric nanoshells for thermal-triggered drug release under hyperthermia conditionInt J Hyper-thermia2015318920929
   PubMed Web of Science ®Google Scholar
• WuCCYangYCHsuYTNanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancerOncotarget2015629268612687526318039
   PubMedGoogle Scholar
• MalamYLoizidouMSeifalianAMLiposomes and nanoparticles: nanosized vehicles for drug delivery in cancerTrends Pharmacol Sci2009301159259919837467
   PubMed Web of Science ®Google Scholar
• JhaveriAMTorchilinVPMultifunctional polymeric micelles for delivery of drugs and siRNAFront Pharmacol201457724795633
   PubMed Web of Science ®Google Scholar
• GabizonACataneRUzielyBProlonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res19945449879928313389
   PubMed Web of Science ®Google Scholar
• GaoHYangZZhangSLigand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalizationSci Rep20133253423982586
   PubMed Web of Science ®Google Scholar
• KesikVHoncaTGulgunMMyostatin as a marker for doxoru-bicin induced cardiac damageAnn Clin Lab Sci2016461263126927339
   PubMedGoogle Scholar
• ShimaHOzasaHTsujiTResponse to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: a case reportMol Clin Oncol20164571571827123268
   PubMedGoogle Scholar
• FuSCulottaKSFalchookGSErratum to: pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastasesCancer Chemother Pharmacol201677488126994910
   PubMedGoogle Scholar
• KrishnamachariYGearySMLemkeCDSalemAKNanoparticle delivery systems in cancer vaccinesPharm Res201128221523620721603
   PubMed Web of Science ®Google Scholar
• BoisselierEAstrucDGold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicityChem Soc Rev20093861759178219587967
   PubMed Web of Science ®Google Scholar
• SantraSJativaSDKaittanisCNormandGGrimmJPerezJMGadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agentACS Nano2012687281729422809405
   PubMedGoogle Scholar
• AlharbiKKAl-SheikhYARole and implications of nanodiagnostics in the changing trends of clinical diagnosisSaudi J Biol Sci201421210911724600302
   PubMedGoogle Scholar
• MenciassiASinibaldiEPensabeneVDarioPFrom miniature to nano robots for diagnostic and therapeutic applicationsConf Proc IEEE Eng Med Biol Soc201020101954195721097006
   PubMedGoogle Scholar
• JordanANanotechnologie und Konsequenzen für chirurgische Onkologie. [Nanotechnology and consequences for surgical oncology]Kongressbd Dtsch Ges Chir Kongr2002119821828 German12704931
   PubMedGoogle Scholar
• ZolnikBSGonzalez-FernandezASadriehNDobrovolskaiaMANanoparticles and the immune systemEndocrinology2010151245846520016026
   PubMed Web of Science ®Google Scholar
• KasturiSPSkountzouIAlbrechtRAProgramming the magnitude and persistence of antibody responses with innate immunityNature2011470733554354721350488
   PubMed Web of Science ®Google Scholar
• SiddiqiNJEffect of gold nanoparticles on superoxide dismutase and indoleamine 2,3-dioxygenase in various rat tissuesIndian J Biochem Biophys201451215615924980020
   PubMedGoogle Scholar
• BriggerIDubernetCCouvreurPNanoparticles in cancer therapy and diagnosisAdv Drug Deliv Rev200254563165112204596
   PubMed Web of Science ®Google Scholar
• AdiseshaiahPPCristRMHookSSMcNeilSENanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancerNat Rev Clin Oncol2016131275076527531700
   PubMed Web of Science ®Google Scholar
• ViswanathBKimSLeeKRecent insights into nanotechnology development for detection and treatment of colorectal cancerInt J Nanomedicine2016112491250427330292
   PubMedGoogle Scholar
• ChenJShaoRZhangXDChenCApplications of nanotechnology for melanoma treatment, diagnosis, and theranosticsInt J Nanomedicine201382677268823926430
   PubMed Web of Science ®Google Scholar
• ChenJGuWYangLNanotechnology in the management of cervical cancerRev Med Virol201525Suppl 1728325752817
   PubMed Web of Science ®Google Scholar
• SugimotoHOdaSOtsukiTHinoTYoshidaTShiroYCrystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenaseProc Natl Acad Sci U S A200610382611261616477023
   PubMed Web of Science ®Google Scholar
• MellorALChandlerPLeeGKIndoleamine 2,3-dioxygenase, immunosuppression and pregnancyJ Reprod Immunol2002571–214315012385839
   PubMedGoogle Scholar
• MellorAIndoleamine 2,3 dioxygenase and regulation of T cell immunityBiochem Biophys Res Commun20053381202416157293
   PubMed Web of Science ®Google Scholar
• BoassoAHerbeuvalJPHardyAWHIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cellsBlood200710983351335917158233
   PubMedGoogle Scholar
• PlattenMWickWVan den EyndeBJTryptophan catabolism in cancer: beyond IDO and tryptophan depletionCancer Res201272215435544023090118
   PubMed Web of Science ®Google Scholar
• SolimanHRawalBFulpJAnalysis of indoleamine 2-3 dioxy-genase (IDO1) expression in breast cancer tissue by immunohistochem-istryCancer Immunol Immunother201362582983723344392
   PubMedGoogle Scholar
• SakuraiKEnomotoKKitajimaATaniMAmanoSShionoMIndoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapyGan To Kagaku Ryoho2008351222652267 Japanese19106591
   PubMedGoogle Scholar
• BasuGDTinderTLBradleyJMCyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDOJ Immunol200617742391240216888001
   PubMed Web of Science ®Google Scholar
• SakuraiKFujisakiSNagashimaSStudy of indoleamine 2,3-dioxygenase expression in patients of thyroid cancerGan To Kagaku Ryoho2011381219271929 Japanese22202241
   PubMedGoogle Scholar
• WitkiewiczAKCostantinoCLMetzRGenotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active targetJ Am Coll Surg20092085781787 discussion 787–78919476837
   PubMed Web of Science ®Google Scholar
• WitkiewiczAWilliamsTKCozzitortoJExpression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detectionJ Am Coll Surg20082065849854 discussion 854–84618471709
   PubMedGoogle Scholar
• Feder-MengusCWylerSHudolinTHigh expression of indoleam-ine 2,3-dioxygenase gene in prostate cancerEur J Cancer200844152266227518619832
   PubMedGoogle Scholar
• KallbergEWikstromPBerghAIvarsFLeandersonTIndoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer modelProstate201070131461147020687219
   PubMedGoogle Scholar
• XieQWangLZhuBWangYGuJChenZThe expression and significance of indoleamine-2,3-dioxygenase in non-small cell lung cancer cellZhongguo Fei Ai Za Zhi2008111115119 Chinese20727279
   PubMedGoogle Scholar
• KaranikasVZamanakouMKerenidiTIndoleamine 2,3-dioxygenase (IDO) expression in lung cancerCancer Biol Ther2007681258126217700060
   PubMed Web of Science ®Google Scholar
• InabaTInoKKajiyamaHIndoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomyGynecol Oncol2010117342342820350764
   PubMedGoogle Scholar
• InoKIndoleamine 2,3-dioxygenase and immune tolerance in ovarian cancerCurr Opin Obstet Gynecol2011231131820930628
   PubMedGoogle Scholar
• MaxDKuhnolCDBurdachSNiuLStaegeMSFollJLIndoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcomaAnticancer Res201434116431644125368243
   PubMedGoogle Scholar
• KoorellaCNairJRMurrayMECarlsonLMWatkinsSKLeeKPNovel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cellsJ Biol Chem2014289117747776224415757
   PubMedGoogle Scholar
• MohmeMRiethdorfSPantelKCirculating and disseminated tumour cells – mechanisms of immune surveillance and escapeNat Rev Clin Oncol Epub2016920
   PubMedGoogle Scholar
• BedognettiDMaccalliCBaderSBMarincolaFMSeligerBCheckpoint inhibitors and their application in breast cancerBreast Care (Basel)201611210811527239172
   PubMedGoogle Scholar
• ManjiliMHButlerSERole of tregs in cancer dormancy or recurrenceImmunol Invest201645875976627603507
   PubMed Web of Science ®Google Scholar
• ShinDSRibasAThe evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next?Curr Opin Immunol201533233525621841
   PubMed Web of Science ®Google Scholar
• MunnDHMellorALIndoleamine 2,3-dioxygenase and tumor-induced toleranceJ Clin Invest200711751147115417476344
   PubMed Web of Science ®Google Scholar
• KatzJBMullerAJPrendergastGCIndoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escapeImmunol Rev200822220622118364004
   PubMed Web of Science ®Google Scholar
• MullerAJScherlePATargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitorsNat Rev Cancer20066861362516862192
   PubMed Web of Science ®Google Scholar
• AlvaroTLejeuneMSalvadoMTOutcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cellsClin Cancer Res20051141467147315746048
   PubMed Web of Science ®Google Scholar
• MullerAJMalachowskiWPPrendergastGCIndoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitorsExpert Opin Ther Targets20059483184916083346
   PubMed Web of Science ®Google Scholar
• WhitesideTLImmune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventionSemin Cancer Biol200616131516153857
   PubMed Web of Science ®Google Scholar
• SonoMEnzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectorsBiochemistry19892813540054072789077
   PubMedGoogle Scholar
• JiangTSunYYinZFengSSunLLiZResearch progress of indoleamine 2,3-dioxygenase inhibitorsFuture Med Chem20157218520125686005
   PubMedGoogle Scholar
• KoblishHKHansburyMJBowmanKJHydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumorsMol Cancer Ther20109248949820124451
   PubMed Web of Science ®Google Scholar
• GrantRKapoorVInhibition of indoleamine 2,3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levelsBiochem Pharmacol20036661033103612963490
   PubMedGoogle Scholar
• SheridanCIDO inhibitors move center stage in immuno-oncologyNat Biotechnol201533432132225850038
   PubMed Web of Science ®Google Scholar
• CadySGSonoM1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenaseArch Biochem Biophys199129123263331952947
   PubMedGoogle Scholar
• WirthgenEKanitzETuchschererMPharmacokinetics of 1-methyl-L-tryptophan after single and repeated subcutaneous application in a porcine modelExp Anim201665214715526725587
   PubMedGoogle Scholar
• UyttenhoveCPilotteLTheateIEvidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNat Med20039101269127414502282
   PubMed Web of Science ®Google Scholar
• Di PucchioTDaneseSDe CristofaroRRutellaSInhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compoundsExpert Opin Ther Pat201020222925020100004
   PubMedGoogle Scholar
• HouDYMullerAJSharmaMDInhibition of indoleamine 2,3- dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responsesCancer Res200767279280117234791
   PubMed Web of Science ®Google Scholar
• JeongYIKimSWJungIDCurcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cellsJ Biol Chem200928463700370819075017
   PubMedGoogle Scholar
• LiuXNewtonRCFriedmanSMScherlePAIndoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapyCurr Cancer Drug Targets20099893895220025603
   PubMedGoogle Scholar
• TakeiYKunikataTAgaMTryptanthrin inhibits interferon-gamma production by Peyer’s patch lymphocytes derived from mice that had been orally administered staphylococcal enterotoxinBiol Pharm Bull200326336536712612449
   PubMedGoogle Scholar
• GaspariPBanerjeeTMalachowskiWPStructure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitorsJ Med Chem200649268469216420054
   PubMedGoogle Scholar
• RohrigUFMajjigapuSRVogelPZoeteVMichielinOChallenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorsJ Med Chem201558249421943725970480
   PubMed Web of Science ®Google Scholar
• TourinoMCde OliveiraEMBelleLPTryptamine and dim-ethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cellsCell Biochem Funct201331536136423754498
   PubMed Web of Science ®Google Scholar
• OgawaKHaraTShimizuM(–)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cellsOncol Lett20124354655023741252
   PubMedGoogle Scholar
• JennyMWondrakAZvetkovaECrinum latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cellsSci Pharm201179232333521773069
   PubMedGoogle Scholar
• KuehnlSSchroecksnadelSTemmlVLignans from Carthamus tinctorius suppress tryptophan breakdown via indoleamine 2,3-dioxygenasePhytomedicine201320131190119523867649
   PubMedGoogle Scholar
• KewitzSVolkmerIStaegeMSCurcuma contra cancer? Curcumin and Hodgkin’s lymphomaCancer Growth Metastasis20136355224665206
   PubMedGoogle Scholar
• MitscherLABakerWTuberculosis: a search for novel therapy starting with natural productsMed Res Rev19981863633749828037
   PubMedGoogle Scholar
• YangSLiXHuFDiscovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing miceJ Med Chem201356218321833124099220
   PubMed Web of Science ®Google Scholar
• RoySBarikSBanerjeeSNeem leaf glycoprotein overcomes indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patientsHum Immunol20137481015102323628394
   PubMedGoogle Scholar
• PeiKOuJHuangJOuSp-Coumaric acid and its conjugates: dietary sources, pharmacokinetic properties and biological activitiesJ Sci Food Agric20169692952296226692250
   PubMed Web of Science ®Google Scholar
• KimSIJeongYIJungIDp-Coumaric acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cellsInt Immunopharmacol20077680581517466914
   PubMed Web of Science ®Google Scholar
• ChenTSArslanFYinYEnabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCsJ Transl Med201194721513579
   PubMed Web of Science ®Google Scholar
• ChenSCortelingRStevanatoLSindenJNatural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cellsBiochem Biophys Res Commun20124291–211712323063682
   PubMed Web of Science ®Google Scholar
• JangJPJangJHSoungNKBenzomalvin E, an indoleamine 2,3-dioxygenase inhibitor isolated from Penicillium sp. FN070315J Antibiot (Tokyo)201265421521722318334
   PubMed Web of Science ®Google Scholar
• JangJPJangJHOhMInhibition of indoleamine 2,3-dioxygenase by thielavin derivatives from a soil fungus, Coniochaeta sp. 10F058J Antibiot (Tokyo)201467433133324326340
   PubMedGoogle Scholar
• FlickHELalondeJMMalachowskiWPMullerAJThe tumor-selective cytotoxic agent beta-Lapachone is a potent inhibitor of IDO1Int J Tryptophan Res20136354524023520
   PubMedGoogle Scholar
• BrastianosHCVotteroEPatrickBOExiguamine A, an indoleam-ine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exiguaJ Am Chem Soc200612850160461604717165752
   PubMedGoogle Scholar
• VotteroEBalgiAWoodsKInhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeastBiotechnol J20061328228816897708
   PubMedGoogle Scholar
• EguchiNWatanabeYKawanishiKHashimotoYHayaishiOInhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivativesArch Biochem Biophys198423226026096431906
   PubMedGoogle Scholar
• KumarSJallerDPatelBStructure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenaseJ Med Chem200851164968497718665584
   PubMedGoogle Scholar
• SchroecksnadelKWinklerCWirleitnerBSchennachHFuchsDAspirin down-regulates tryptophan degradation in stimulated human peripheral blood mononuclear cells in vitroClin Exp Immunol20051401414515762873
   PubMed Web of Science ®Google Scholar
• SayamaSYoshidaROkuTImanishiJKishidaTHayaishiOInhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesisProc Natl Acad Sci U S A19817812732773306174971
   PubMedGoogle Scholar
• ThomasSRStockerRRedox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathwayRedox Rep19994519922010731095
   PubMed Web of Science ®Google Scholar
• BanerjeeTDuhadawayJBGaspariPA key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenaseOncogene200827202851285718026137
   PubMedGoogle Scholar
• MehtaRGLiuJConstantinouACancer chemopreventive activity of brassinin, a phytoalexin from cabbageCarcinogenesis19951623994047859373
   PubMed Web of Science ®Google Scholar
• ParkEJPezzutoJMBotanicals in cancer chemopreventionCancer Metastasis Rev2002213–423125512549763
   PubMed Web of Science ®Google Scholar
• Alberati-GianiDMalherbePRicciardi-CastagnoliPKohlerCDenis-DoniniSCesuraAMDifferential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cellsJ Immunol199715914194269200481
   PubMed Web of Science ®Google Scholar
• DaubenerWPosdziechVHaddingUMacKenzieCRInducible anti-parasitic effector mechanisms in human uroepithelial cells: tryptophan degradation vs. NO productionMed Microbiol Immunol1999187314314710206145
   PubMedGoogle Scholar
• HuckeCMacKenzieCRAdjogbleKDTakikawaODaubenerWNitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenaseInfect Immun20047252723273015102781
   PubMedGoogle Scholar
• SonoMRoachMPCoulterEDDawsonJHHeme-containing oxygenasesChem Rev19969672841288811848843
   PubMed Web of Science ®Google Scholar
• RöhrigUFAwadLGrosdidierARational design of indoleamine 2,3-dioxygenase inhibitorsJ Med Chem20105331172118920055453
   PubMed Web of Science ®Google Scholar
• DolusicELarrieuPBlancSDiscovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitorsEur J Med Chem20114673058306521419531
   PubMed Web of Science ®Google Scholar
• DolusicELarrieuPBlancSIndol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitorsBioorg Med Chem20111941550156121269836
   PubMed Web of Science ®Google Scholar
• PasceriRSiegelDRossDMoodyCJAminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin AJ Med Chem20135683310331723521768
   PubMedGoogle Scholar
• SingerELinehanJBabiloniaGStromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasiaPLoS One201386e6056223762225
   PubMedGoogle Scholar
• KhanNBharaliDJAdhamiVMOral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft modelCarcinogenesis201435241542324072771
   PubMed Web of Science ®Google Scholar
• MajumdarDJungKHZhangHLuteolin nanoparticle in chemo-prevention: in vitro and in vivo anticancer activityCancer Prev Res (Phila)201471657324403290
   PubMed Web of Science ®Google Scholar
• LiYLinTYLuoYA smart and versatile theranostic nanomedi-cine platform based on nanoporphyrinNat Commun20145471225158161
   PubMed Web of Science ®Google Scholar
• SedlmayrPSemlitschMGebruGExpression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervixAdv Exp Med Biol2003527919515206720
   PubMedGoogle Scholar
• KaiSGotoSTaharaKSasakiAKawanoKKitanoSInhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growthJ Exp Ther Oncol20033633634514678522
   PubMedGoogle Scholar
• ChungTWTanKTChanHLInduction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity contributes to interferon-gamma induced apoptosis and death receptor 5 expression in human non-small cell lung cancer cellsAsian Pac J Cancer Prev201415187995800125292102
   PubMedGoogle Scholar
• ChenSSCortelingRStevanatoLSindenJPolyphenols inhibit indoleamine 3,5-dioxygenase-1 enzymatic activity – a role of immunomodulation in chemopreventionDiscov Med2012147832733323200064
   PubMedGoogle Scholar
• BrandacherGWinklerCSchroecksnadelKMargreiterRFuchsDAntitumoral activity of interferon-gamma involved in impaired immune function in cancer patientsCurr Drug Metab20067659961216918315
   PubMedGoogle Scholar
• LiXLuWLLiangGWEffect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in miceEur J Clin Invest200636640941816684125
   PubMedGoogle Scholar
• AgrawalVPaulMKMukhopadhyayAK6-Mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterizationJ Liposome Res2005153–414115516393906
   PubMed Web of Science ®Google Scholar
• WuJLuYLeeAReversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamilJ Pharm Pharm Sci200710335035717727798
   PubMed Web of Science ®Google Scholar
• TekadeRKDuttaTTyagiABhartiACDasBCJainNKSurface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategyJ Drug Target2008161075877218985508
   PubMed Web of Science ®Google Scholar
• ZhangJYangPLGrayNSTargeting cancer with small molecule kinase inhibitorsNat Rev Cancer200991283919104514
   PubMed Web of Science ®Google Scholar
• TranMASmithCDKesterMRobertsonGPCombining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor developmentClin Cancer Res200814113571358118519791
   PubMed Web of Science ®Google Scholar
• DilnawazFSinghAMohantyCSahooSKDual drug loaded super-paramagnetic iron oxide nanoparticles for targeted cancer therapyBiomaterials201031133694370620144478
   PubMed Web of Science ®Google Scholar
• LammersTSubrVUlbrichKSimultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriersBiomaterials200930203466347519304320
   PubMed Web of Science ®Google Scholar
• LeeIHAnSYuMKKwonHKImSHJonSTargeted chemoim-munotherapy using drug-loaded aptamer-dendrimer bioconjugatesJ Control Release2011155343544121641946
   PubMed Web of Science ®Google Scholar
• RenYKangCSYuanXBCo-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitroJ Biomater Sci Polym Ed201021330331420178687
   PubMed Web of Science ®Google Scholar
• KaneshiroTLLuZRTargeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrierBiomaterials200930295660566619595449
   PubMed Web of Science ®Google Scholar
• KangSHChoHJShimGCationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacyPharm Res201128123069307821879387
   PubMed Web of Science ®Google Scholar
• XiaoWChenXYangLMaoYWeiYChenLCo-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic lipo-someInt J Pharm20103931–211912620416367
   PubMedGoogle Scholar
• ZuckerDBarenholzYOptimization of vincristine-topotecan combination – paving the way for improved chemotherapy regimens by nanoliposomesJ Control Release2010146332633320685223
   PubMed Web of Science ®Google Scholar
• SongXRZhengYHeGDevelopment of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinomaJ Pharm Sci201099124874487920821385
   PubMed Web of Science ®Google Scholar
• BatistGGelmonKAChiKNSafety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsClin Cancer Res200915269270019147776
   PubMed Web of Science ®Google Scholar
• TardiPJohnstoneSHarasymNIn vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacyLeuk Res200933112913918676016
   PubMed Web of Science ®Google Scholar
• HamiltonABiganzoliLColemanREORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancerAnn Oncol200213691091812123337
   PubMed Web of Science ®Google Scholar
• BedikianAYSilvermanJAPapadopoulosNEPharmacokinet-ics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver functionJ Clin Pharmacol20115181205121220978276
   PubMedGoogle Scholar
• SilvermanJADeitcherSRMarqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristineCancer Chemother Pharmacol201371355556423212117
   PubMed Web of Science ®Google Scholar
• GillPSWernzJScaddenDTRandomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincris-tine in AIDS-related Kaposi’s sarcomaJ Clin Oncol1996148235323648708728
   PubMedGoogle Scholar
• BellottRAuvrignonALeblancTPharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemiaCancer Chemother Pharmacol2001471152111221955
   PubMed Web of Science ®Google Scholar
• LuDBurrisHA3rdWangBDrug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancerCurr Drug Metab201213791192222475266
   PubMedGoogle Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• BradleyAMDevineMDeRemerDBrentuximab vedotin: an anti-CD30 antibody-drug conjugateAm J Health System Pharm201370758959723515511
   PubMed Web of Science ®Google Scholar
• AndoMYonemoriKKatsumataNPhase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancerCancer Chemother Pharmacol201269245746521853310
   PubMedGoogle Scholar
• WatkinsRWuLZhangCDavisRMXuBNatural product-based nanomedicine: recent advances and issuesInt J Nanomedicine2015106055607426451111
   PubMed Web of Science ®Google Scholar